Seeking Alpha

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Seeking Alpha

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Inside Higher Ed

Report: Inclusive-Access Models as a Lever for Student Success

You have /3 articles left. Sign up for a free account or log in. Costly course materials can impede student access and success in the classroom. Over half of college ...
World Bank

Energy Access Has Improved, Yet International Financial Support Still Needed to Boost Progress and Address Disparities

New report urges scaled-up tailored financial support for decentralised renewable energy to reach 666 million people in rural and vulnerable areas in developing countries. Washington, New York, Paris, ...